Metabolic syndrome and cardiovascular risk between clozapine and non-clozapine antipsychotic users with schizophrenia

Clozapine use is associated with higher risks of metabolic side effects and cardiovascular diseases (CVD). Thus, this study aims to establish and compare the cardiometabolic profiles between non-clozapine antipsychotic and clozapine users with schizophrenia. Data from 88 non-clozapine and 166 clozapine users were extracted from existing databases - demographics, medications, smoking and medical histories, anthropometric parameters, serum lipid and fasting glucose levels. Prevalence of metabolic syndrome (MetS) was established using the AHA/NHLBI criteria. Cardiovascular risk profiles were established using the Framingham risk score (FRS). The clozapine group had significantly higher proportions of diagnosed hypertension (10.8% vs. 3.4%, p = 0.041), diabetes mellitus (15.7% vs. 3.4%, p = 0.003) and dyslipidemia (36.7% vs. 12.5%, p < 0.001). However, the non-clozapine antipsychotic group had poorer anthropometric, serum lipids and glucose levels. The prevalence rates of MetS in the clozapine and non-clozapine antipsychotic groups were not statistically significant at 42.8% and 43.2%, respectively. As for CVD risk, the non-clozapine antipsychotic group had significantly higher FRS (6.59% vs. 6.12%, p = 0.001). Although clozapine users had higher rates of diagnosed metabolic conditions, other cardiometabolic parameters appeared better compared to non-clozapine antipsychotic users, which could be due to greater awareness, earlier detection and treatment. Regardless of the type of antipsychotic used, metabolic abnormalities are prevalent in individuals with schizophrenia; physical healthcare should be prioritized alongside mental healthcare in this group. •Comparable prevalence rates of Metabolic Syndrome (MetS) in clozapine and non-clozapine antipsychotics users with schizophrenia.•Clozapine users have lower 10-year cardiovascular disease (CVD) risk than their non-clozapine antipsychotic counterparts – likely due to early detection and treatment of metabolic disorders.•Poor detection of metabolic abnormalities in the non-clozapine antipsychotics users with schizophrenia.